FTSE MIB
33.321,85 -632,43 (-1,86%) Dow Jones
37.805,38 +70,27 (+0,19%) Nasdaq
15.873,10 -11,92 (-0,08%) Nikkei 225
38.471,20 -761,60 (-1,94%) Petrolio
85,57 +0,16 (+0,19%) Bitcoin EUR
58.410,26 -2.126,55 (-3,51%)
Biogen Inc. (BIIB)
| Chiusura precedente | 196,80 |
| Aperto | 196,20 |
| Denaro | 196,30 x 200 |
| Lettera | 208,32 x 100 |
| Min-Max giorno | 195,06 - 197,42 |
| Intervallo di 52 settimane | 195,06 - 319,76 |
| Volume | |
| Media Volume | 1.181.716 |
| Capitalizzazione | 28,563B |
| Beta (5 anni mensile) | -0,01 |
| Rapporto PE (ttm) | 24,65 |
| EPS (ttm) | 7,97 |
| Prossima data utili | 24 apr 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 300,70 |
GlobeNewswireFDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®
TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United StatesFDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA.
- GlobeNewswire
Biogen Completes Acquisition of Reata Pharmaceuticals
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of the transact
- GlobeNewswire
LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
TOKYO and CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody LEQEMBI® Intravenous Infusion (200 mg, 500mg, lecanemab) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment (MC
